Growth Hormone · 5mg × 10 vials
Short-acting GHRH (1-29) analog. Milder GH pulse than CJC-1295 no-DAC; the classic entry compound in GH-axis research.
Sermorelin is a 29-amino-acid fragment of human growth-hormone-releasing hormone (GHRH 1-29), the shortest native sequence that retains full biological activity. It binds the GHRH receptor on the somatotroph cells of the anterior pituitary and stimulates synthesis and pulsatile release of the body's own growth hormone. Because the somatostatin negative-feedback loop remains intact, GH release is self-limiting, and IGF-1 does not rise to the supraphysiological levels seen with exogenous somatropin.
The downstream GH pulse drives hepatic IGF-1 production, the mediator of GH's effects on body composition and tissue repair. Plasma half-life is short, roughly 11 to 12 minutes, and the published studies note that evening administration coincides with the natural overnight GH surge during slow-wave sleep, amplifying that pulse rather than creating a separate one. Sermorelin shares its receptor target with tesamorelin and the GHRH arm of CJC-1295 but is shorter-acting and less potent. It was FDA-approved as Geref for paediatric GH deficiency and as a diagnostic agent before being withdrawn from the US market for commercial reasons in 2008.
What the published studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
foundational adult-use mechanism review, GHRH 1-29 biology
Read study ↗PubMedGeref International Study Group - Once daily subcutaneous GHRH accelerates growth in GH-deficient childrenpivotal pediatric trial, 30 mcg/kg, height velocity 4.1 → 8.0 cm/yr
Read study ↗PubMedPrakash A & Goa KL - Sermorelin: review of its use in idiopathic GH deficiencyefficacy + AE rates, the ~16% injection site reaction figure comes from this dataset
Read study ↗PubMedKhorram O, Laughlin GA, Yen SS - Endocrine and metabolic effects of long-term GHRH(1-29) in age-advanced men and women, JCEM 1997;82(5):1472-1479in age-advanced men and women, JCEM 1997;82(5):1472-1479](https://pubmed.ncbi.nlm.nih.gov/9141539/) - the cornerstone anti-aging study: 16 weeks nightly GHRH analog, +1.26 kg lean body mass, increased skin thickness, improved IS, IGF-1 levels approaching those of younger adults
Read study ↗PubMedVance ML - Growth hormone-releasing hormone, Clinical Chemistry 1990original GHRH biology, half-life, pulse mechanism
Read study ↗Clinical referenceSermorelin Wikipedia entry - FDA history, Geref withdrawal 2008FDA approval 1997, withdrawn 2008 for commercial reasons (not safety)
Read study ↗Storage: refrigerated, 14-28 days after reconstitution. Sermorelin is more freshness-sensitive than CJC-1295 with DAC (no albumin tail to protect it) but more stable than ipamorelin in solution. Toss at 30 days regardless.